Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2016 01:00 ET | Source: Novartis Pharma AG

Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)

Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care...
December 09, 2016 08:30 ET | Source: Novartis Pharma AG

Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole

MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone LEE011...
December 08, 2016 01:15 ET | Source: Novartis Pharma AG

Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment

Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the 2017...
December 07, 2016 01:15 ET | Source: Novartis Pharma AG

Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions

The European Commission approved Lucentis to treat patients for visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular...
December 06, 2016 03:45 ET | Source: Novartis Pharma AG

Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC

Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC[1] Patients with...
December 05, 2016 13:30 ET | Source: Novartis Pharma AG

Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®

ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients[1] The Tasigna TFR trials, including ENESTop, demonstrate our continued...
December 05, 2016 13:00 ET | Source: Novartis Pharma AG

Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work

Findings across six countries and four continents showed a reduction in quality of life for majority (71%) of patients living with myeloproliferative neoplasms (MPNs)[1] Patients reported a...
December 05, 2016 01:15 ET | Source: Novartis Pharma AG

New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1] Interim data in over...
December 03, 2016 19:00 ET | Source: Novartis Pharma AG

Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL

82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T...
December 03, 2016 13:00 ET | Source: Novartis Pharma AG

Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study

SEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy SEG101 is a potential new disease-modifying,...